|
16 Aug 2019 |
News |
Upadacitinib (RINVOQ) FDA Approved for Rheumatoid Arthritis |
|
|
14 Aug 2019 |
Social |
Lilly announces the results of its phase 4 trial comparing Taltz (IL-17) to Tremfya (IL-23) in mod-severe plaque psoriasis. Taltz had superior skin clearance (PASI 100) at week 12, better PASI 75 at week 2 and PASI 90 at weeks 4 and 8. https://t.co/GzfZoepUrK |
|
|
13 Aug 2019 |
Social |
RT @RheumNow: In GCA/Temporal arteritis, when do you start a DMARD/Biologic? |
|
|
12 Aug 2019 |
Social |
In GCA/Temporal arteritis, when do you start a DMARD/Biologic? |
|
|
09 Aug 2019 |
Social |
Amgen wins U.S. patent battle against Novartis over Enbrel patents, delaying Novartis' attempts to launch its etanercept biosimilar Erelzi until (possibly) 2029. Novartis intends to appeal. https://t.co/uoEQJJUf9A |
|
|
06 Aug 2019 |
News |
Are Non-TNF Biologics Superior to TNF inhibitors? |
|
|
06 Aug 2019 |
Social |
FDA has approved Turalio (pexidartinib) for the treatment of adults with the rare disorder, tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery. https://t.co/eMTmFSW97A |
|
|
04 Aug 2019 |
Social |
Measures used to limit costs & utilization of expensive biologics: 1) Generics 1st requirement; 2) Pre-authorization; 3) limited (6-9 mos) approval w/ proof of benefit; 4) 30 day supply; 5) preferred tiered drugs; & 6) utilize less expensive providers https://t.co/2HRrJn87AY |
|
|
29 Jul 2019 |
Social |
Measures used to limit costs & utilization of expensive biologics: 1) Generics 1st requirement; 2) Pre-authorization; 3) limited (6-9 mos) approval w/ proof of benefit; 4) 30 day supply; 5) preferred tiered drugs; & 6) utilize less expensive providers https://t.co/2HRrJn87AY |
|
|
27 Jul 2019 |
Social |
The FDA Arthritis Advisory Committee voted 10-7 in favor of approving the to consider the antifibrotic drug, nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) https://t.co/UNlpQNJAim |
|
|
26 Jul 2019 |
Social |
Samsung Bioepsis has announced an update to the EU product label for its adalimumab biosimilar IMRALDI - adding the drug can be stored in non-refrigerated conditions (up to 25˚C or 77F) for up to 28 days https://t.co/nGgxZDBQyC |
|
|
25 Jul 2019 |
Social |
FDA has approved Ruxience (rituximab-pvvr; Pfizer), a biosimilar to Rituxan for use in NHL, CLL, granulomatosis w/ polyangiitis (GPA) & microscopic polyangiitis;(NOT RA) THis is the 2nd RTX biosimilar. https://t.co/GuVG6S980j |
|
|
24 Jul 2019 |
Social |
FDA has approved a new biosimilar Hadlima (adalimumab-bwwd), from Samsung Bioepis, for the same indications as Humira (RA, pJIA, PsA, AS, Crohn’s, UC, plaque psoriasis), but the drug won't be available in the U.S. until June 2023. https://t.co/h4oqwFjR0c |
|
|
24 Jul 2019 |
News |
FINCH2: Filgotinib in Biologic Refractory Rheumatoid Arthritis |
|
|
15 Jul 2019 |
News |
Rituximab Safety Concerns when Used in anti-TNF Refractory RA |
|
|
15 Jul 2019 |
Social |
Do biologics work in relapsing polychondritis? French cohort of 41 pts use 105 biologics (TNFi=60; TCZ 17; anakinra 15; RTX 7; ABA6). While 63% resp in 1st 6 mos (on pred!), a complete response rate was 19.0%. Steroid sparing variable, high infx rates. https://t.co/Ff9KULlKVD |
|
|
28 Jun 2019 |
Social |
FDA has announced that on July 25th it will hold an Arthritis Advisory Committee Meeting to discuss Boehringer Ingelheims application for Nintedanib use in systemic sclerosis-associated interstitial lung disease (SSc-ILD) https://t.co/z4uLJ8hdyX |
|
|
24 Jun 2019 |
Social |
"Therapeutic Update: Biosimilars in Rheumatology" video series features nine experts talking about biosimilars, sponsored by Sandoz, Inc. Visit RheumNow to watch: https://t.co/1vmnEJqOSi #sponsored #biosimilars |
|
|
21 Jun 2019 |
Social |
RT @LCalabreseDO: Give me your take for my next ED in @HealioRheum on DTC-Direct to-consumer adverstising of Drugs/Biologics (as seen on na… |
|
|
21 Jun 2019 |
Social |
Hear nine experts talk about biosimilars in “Therapeutic Update: Biosimilars in Rheumatology”, a video series brought to viewers by Sandoz. Now available on RheumNow. https://t.co/1vmnEJqOSi #sponsored #biosimilars https://t.co/EXf19NB6g8 |
|
